The short answer
Tirzepatide appears as the comparator in SURMOUNT-5 against semaglutide, in REDEFINE 4 against CagriSema, and in TRIUMPH-5 against retatrutide. It has become the standard a new obesity compound is expected to be tested against.
Key facts
- SURMOUNT-5
- Tirzepatide 20.2% vs semaglutide 13.7%
- REDEFINE 4
- Tirzepatide 25.5% vs CagriSema 23.0%
- TRIUMPH-5
- vs retatrutide (primary completion scheduled Nov 2026)
- REDEFINE 4 registration
- NCT06131437, n=809, completed
- TRIUMPH-5 registration
- NCT06662383, n=800, active
- Common feature
- Tirzepatide is the reference arm
How a benchmark forms
A compound becomes the comparator when beating it is what the field considers meaningful. Tirzepatide reached that position by winning the one direct comparison against semaglutide that mattered: SURMOUNT-5 randomised 751 adults over 72 weeks and reported 20.2% against 13.7%. After that, showing superiority to semaglutide stopped being sufficient.
Why sponsors run these trials at all
They are risky. A head-to-head against a strong comparator can produce a result the sponsor did not want, publicly and irreversibly, as happened to Novo Nordisk in REDEFINE 4. Running one signals confidence, and prescribers and payers increasingly expect the evidence rather than accepting cross-trial comparison.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the three trials are not
Comparable with each other. SURMOUNT-5 ran 72 weeks, REDEFINE 4 ran 84, TRIUMPH-5 is a different population again. Tirzepatide's reported figure differs between them (20.2% in one, 25.5% in another), and that difference reflects trial design, duration and population rather than the drug changing. Reading across them as a league table is the error head-to-heads exist to prevent.
Why tirzepatide's own number moves
Different durations, different populations, different estimands. In REDEFINE 4 the efficacy estimand gave 25.5% and the treatment-policy estimand 23.6%, a 1.9 point gap within one trial, from the same participants, reflecting only how discontinuation is handled. A figure quoted without its estimand cannot be compared with anything.
What TRIUMPH-5 will and will not settle
Registered as NCT06662383, active and not recruiting, 800 participants, primary completion scheduled for November 2026. Because retatrutide and tirzepatide are both Lilly molecules built on modified GIP scaffolds, the comparison isolates the glucagon receptor arm about as cleanly as a trial can. It will not tell you how retatrutide compares with CagriSema, because nobody has run that trial.
The regulatory point that gets lost
Tirzepatide and semaglutide are licensed medicines. CagriSema is filed and unapproved. Retatrutide is investigational. A table of weight-loss percentages flattens a group of compounds at completely different regulatory stages into apparent equivalents, and none of them has any relationship to research material.
Quick reference
| Trial | Comparison | Duration | Status |
|---|---|---|---|
| SURMOUNT-5 | Tirzepatide vs semaglutide | 72 weeks | Reported |
| REDEFINE 4 | CagriSema vs tirzepatide | 84 weeks | Completed Jan 2026 |
| TRIUMPH-5 | Retatrutide vs tirzepatide | - | Primary completion scheduled Nov 2026 |
Frequently asked questions
Why is tirzepatide the comparator in so many trials?
It won the direct comparison against semaglutide in SURMOUNT-5, after which beating semaglutide alone stopped being a meaningful claim.
Can I rank these compounds from the three trials?
No. Different durations, populations and estimands. Tirzepatide's own reported figure differs between them for those reasons alone.
Why do sponsors risk head-to-heads?
Prescribers and payers increasingly expect direct evidence, and running one signals confidence, though REDEFINE 4 shows the risk is real.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5, retatrutide vs tirzepatide (NCT06662383)clinicaltrials.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
- PubMedHamarsheh S et al., Comparative effectiveness of CagriSema, semaglutide, cagrilintide and tirzepatide. Endocrinol Diabetes Metab 2026 (PMID 42207966)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Open-Label Does to a Weight-Loss TrialREDEFINE 4's registry record lists masking as none. Why an unblinded weight trial is weaker evidence, and where the effect creeps in.
- Two Answers to the Same QuestionCagriSema pairs GLP-1 with amylin; tirzepatide pairs it with GIP. REDEFINE 4 was effectively the first direct test between those strategies.
- Semaglutide and Liver Disease: What ESSENCE TestedA 1,205-participant Phase 3 in metabolic dysfunction-associated steatohepatitis, published in NEJM in June 2025. What it measured and why liver trials are hard.
- FLOW: A Kidney Outcome Trial, Stopped Early3,533 participants with type 2 diabetes and chronic kidney disease. What FLOW measured, and why it is a harder kind of evidence than a weight trial.
- SELECT: The Trial That Changed What the Class Was For17,604 participants with obesity and cardiovascular disease but no diabetes. Why studying that population specifically was the point.